Nov. 15 at 9:20 PM
Since 1/1/2013, 90% of new commercial-stage bios not sold within 2 years of FDA approval in oncology & within 3 years in non-oncology deliver losses to shareholders.
90% of those sold within 2 years in oncology & 3 in non-oncology deliver meaningful returns to shareholders, versus their closing share price as of the day after approval.
Of course there are the 10% outliers in both groups. AVDL is the most recent outlier & good for them.
For perspective, attached is a schedule of all new commercial-stage oncology over the last 2 years & non-oncology the last 3 years. The schedule notes all oncology is lower except NUVB.
$KURA is the newest addition to this peer group.
In non-oncology (after the CDTX exit),
$SLNO $ABEO $KALV &
$LENZ were up since approval the last time we published this analysis 2 months ago. They all have flipped since.
This is not investment advice.
